Investors
Corporate Profile
Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from GSDIa, phenylketonuria (PKU), Wilson disease, and citrullinemia; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in OTC deficiency, which is in a Phase 1/2 clinical trial. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.
Presentations
DateTitle
07/10/17
Dimension Therapeutics Corporate Presentation July 2017
Download Documentation
Stock
DMTX (Common Stock) $1.400.00 (0.00%)
High $1.45
Events
Dimension Therapeutics Q4 2016 Earnings and Corporate Update Conference Call
03/09/17 8:30 a.m. ET
E-mail Alerts
Sign up to receive
E-mail Alerts
 
News
June 27, 2017
Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities
Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017 IND filings for GSDIa and Hemophilia A expected in 2018 Operating expenses reduced and cash runway extended CAMBRIDGE, Mass., June 27, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, t[...]  Read More /
May 10, 2017
Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
Discontinues Clinical Development of DTX101, an AAVrh10 Factor IX Gene Therapy Product Candidate for Moderate/Severe-to-Severe Hemophilia B Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector IMD product candidate for OTC Deficiency, expected 2H 2017 CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key o[...]  Read More /
April 24, 2017
Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
CAMBRIDGE, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced poster presentations that highlight technology underpinning select product candidate programs. The presentations will occur during the 20th ASGCT Annual Meeting, which is taking place in Washington, DC, May 10-13, 2017. “We are pleased th[...]  Read More /
Data provided by Nasdaq. Minimum 15 minutes delayed.